Navigation Links
FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
Date:12/10/2009

CAMBRIDGE, Mass., Dec. 10 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) approved Cequent's first IND (investigational new drug) application yesterday. This action enables Cequent to initiate the first-ever trial of an orally administered RNA interference drug in humans: CEQ508 - the company's lead drug candidate based on its proprietary tkRNAi technology. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

The IND application acceptance is the second procedural hurdle that the young company has cleared in order to begin human clinical trials of CEQ508 in the FAP (familial adenomatous polyposis) patient population. The company noted that the 14 reviewing members of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH) voted unanimously to endorse the proposed clinical protocol after conducting an in-depth review and public discussion of the proposed CEQ508 program on September 9, 2009.*

"We submitted our IND application to the FDA on November 9, 2009. Having our first IND application accepted in the 30-day period is an extraordinary accomplishment for any company, particularly so for Cequent, given that we are working on an entirely new class of drugs," said Cequent Chief Executive Officer Peter Parker. "It speaks volumes to the quality of the submission, which comprised more than 4,000 pages. I'm so proud of our scientific team, who, in a short time, were successful in turning an intriguing RNAi research concept into a viable drug candidate ready to be tested in humans."

The FDA approved Cequent's proposed clinical protocol for the Phase I clinical trial, including
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
2. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
3. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
4. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
5. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
6. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
7. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
11. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SOUTH PLAINFIELD, N.J., July 30, 2015 PTC ... corporate update and reported financial results for the second ... is progressing on many fronts across the organization.  We ... largest Duchenne muscular dystrophy clinical trial ever conducted with ... W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
(Date:7/30/2015)... LAKE, N.J. , July 30, 2015 ... simultaneously in the United States , ... the FDA, EMA and MHLW, respectively) for eribulin, for ... (STS) who have received prior chemotherapy for advanced or ... based on data from a pivotal global Phase 3 ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... 24 BioTrends Research Group, Inc. recently published its ... report is based on online ... interventional radiologists and interventional nephrologists). It provides an in-depth ... practice patterns related to both vascular access placement and ...
... Mass., Aug. 24 Echo Therapeutics, Inc. (OTC Bulletin ... needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal ... for transdermal drug delivery, today announced the completion of ... designed to evaluate the ability of Prelude to ablate ...
Cached Medicine Technology:Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market 2Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream 2Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream 3
(Date:8/1/2015)... , ... August 01, 2015 , ... “ reTXT ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers allows users to clarify, edit and delete any message including ones ...
(Date:7/31/2015)... ... , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened ... 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and ... Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... new store run by GoodThreads. The store can be accessed by visiting ... many of which are customizable. The best part: whenever a product is purchased, ...
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... ... to communicate. Rally Insurance Group, Inc. has re-branded their social media profiles to ... a personal way for consumers to communicate, find information, share insights and opinions. ...
(Date:7/31/2015)... ... 31, 2015 , ... According to an article published July 2 ... could reach a consensus on the steps that need to be taken to successfully ... 90 percent consensus on a series of steps that each surgeon must complete for ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... PercuNav System Cart Allows Easier Operation and Improved ... Traxtal Inc., the pioneer and world leader ... a newly designed system cart for the PercuNav ... at Booth # 322 of the Society of ...
... Bioniche Life Sciences Inc. (TSX: BNC), a research-based, ... Company has amended the maturity date of its ... (formerly Laurus Master Funds). , On October 31, ... extension of this facility, originally scheduled to mature ...
... $10 - Plus More Women,s Health MedicationsGRAND RAPIDS, Mich., ... Market, Family Fare and VG,s pharmacies will expand their ... - now there are two programs offering lower prices ... needs and healthcare budgets of our customers. These pharmacies ...
... "Eco Friendly and Green" awards movement, Allstar Awards of Placentia, California, ... is to promote environmentally safe awards as an alternative to the ... ... 2009 -- Striving to be at the forefront of the "Eco ...
... common skin disorders to hepatitis or HIV, is now available in ... peptides induces modulation and regulation of the immune system. GKL03 (Thymrevit) ... , ... Mannheim, Germany -- A new preparation highly beneficial ...
... It,s estimated that more than a half million kids in ... That,s an average of a kid per minute- every minute of ... surprise you to know that almost all of them are treated ... of diagnosing and treating concussions in kids. , 13 ...
Cached Medicine News:Health News:Traxtal to Introduce Next-Generation PercuNav System Cart at SIR Annual Scientific Meeting 2Health News:Bioniche Revolving Credit Facility Maturity Date Amended 2Health News:D&W Fresh Markets, Family Fare and VG's Expand Discounted Generic Drug Program 2Health News:D&W Fresh Markets, Family Fare and VG's Expand Discounted Generic Drug Program 3Health News:D&W Fresh Markets, Family Fare and VG's Expand Discounted Generic Drug Program 4Health News:Allstar Awards Announces its New Ecologically Friendly Product Website 2Health News:Allstar Awards Announces its New Ecologically Friendly Product Website 3Health News:German Medical Advancement Reflects Major Improvement in Individuals with Common and Chronic Illnesses Related to Immune System Dysfunction 2Health News:Classifying concussions could help kids 2Health News:Classifying concussions could help kids 3
... two perforations which enable procedure-specific ... single or bilateral configurations to ... has two perforations which enable ... various single or bilateral configurations ...
Used after ablation to wash away particulate from anterior & posterior sides of flap & stromal bed. Conforms to the corneal flap. .0mm extension with a 11.0mm radius, Angled tip....
Dome shape, extra smooth tip provides safe insertion through wound & manipulation within the eye. 45, 4.0mm from end...
Designed to provide more effective infusion, .90mm(20 G) ultra thinwall cannula with 45 beveled tip allows 30 percent more fluid flow than a regular wall cannula...
Medicine Products: